Last reviewed · How we verify
Noretynodrel (NORETHYNODREL)
At a glance
| Generic name | NORETHYNODREL |
|---|---|
| Sponsor | Pfizer |
| Drug class | norethynodrel |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1961 |
Approved indications
- Contraception
- Endometriosis
- Female hypogonadism syndrome
- Menorrhagia
Common side effects
Drug interactions
- rifabutin
- rifampicin
- rifapentine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Noretynodrel CI brief — competitive landscape report
- Noretynodrel updates RSS · CI watch RSS
- Pfizer portfolio CI